Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

The departure of Biogen's CEO could lead to a sale of the biotech company, or a renewed push to boost its own M&A activities.

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.

Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial

Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial

Brainstorm's NurOwn is a personalized stem cell treatment designed to slow the progression of ALS, a fatal neurodegenerative disease.

XBiotech Colon Cancer Drug Data Deemed Unreliable by European Group

XBiotech Colon Cancer Drug Data Deemed Unreliable by European Group

Serious questions about the XBiotech colon cancer drug were raised after the Xylonix presentation at an ESMO cancer meeting on July 2.

Brain Tumor Patient Dies After Ziopharm Gene Therapy Injection

Brain Tumor Patient Dies After Ziopharm Gene Therapy Injection

The circumstances surrounding the Ziopharm patient deaths come amid heightened scrutiny of experimental anti-cancer therapies.